Why BGPT?
logo

Review Against the Reported Record

Check a paper's claims against linked experiments, exact results, stated scope, and limitations.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Explanation



    Seidler et al. (2017) solved the first atomic structures of tau's VQIINK steric zipper by MicroED (PDB 5V5B, 5K7N), showed VQIINKβ€”not VQIVYKβ€”is the dominant driver of full-length tau aggregation and seeding, and rationally designed peptide inhibitors (W-MINK, M4W39) with sub-3 Β΅M IC50s against tau40 seeding in HEK293 biosensor cells , though all validation is in vitro and in cell culture with no in vivo data.


     Long Explanation



    Core Contribution and Evidence

    Seidler et al. overcame a decade-long failure to crystallize tau's VQIINK segment by using micro-electron diffraction (MicroED), yielding a 1.5 Γ… structure of KVQIINKKLD (PDB 5V5B) and a second polymorph of VQIINK (PDB 5K7N). The ten-residue structure revealed two steric-zipper interfaces (A and B), with shape complementarity Sc = 0.77 and buried area Ab = 168 Γ…Β²β€”substantially more adhesive than VQIVYK's 0.72 and 75 Γ…Β². Engineered K18 constructs confirmed functionally that 2xIN fibrillizes twice as fast as WT (75 vs 150 min half-max), while 2xVY is slowest (225 min) .

    Structure-based design produced MINK/WINK (Phase 1, IC50 22.6/28.9 Β΅M) and Phase 2 inhibitors capping all three interfaces, improving potency ~20-fold (W-MINK 1.1 Β΅M). Notably, the established VQIVYK inhibitor TLKIVW failed to block tau40 seeding, and did not synergize with VQIINK inhibitors (MINK+TLKIVW IC50 52.2 Β΅M) .

    Reconciliation with AD Fibril Structures

    A potential tension: cryo-EM of AD brain-derived tau fibrils shows the core comprises R3/R4, placing VQIINK (R2) in the fuzzy coat . The authors honestly address this, proposing the solvent-exposed fuzzy-coat VQIINK zippersβ€”not the buried coreβ€”drive seeding, and concede the alternative that in vitro fibril cores differ from AD cores. This remains unresolved and is the paper's weakest inferential link.

    Critical Appraisal

    • Strengths: Atomic-level structures (deposited PDB 5V5B, 5K7N), clear mechanistic explanation of Ξ”K280 acceleration (merged A+B interface, Ab β‰ˆ 299 Γ…Β²), triplicate ThT assays, blinding reported, honest polymorph speculation framed as needing future validation .
    • Limitations: Heparin-accelerated aggregation may not reflect physiological aggregation; HEK293 biosensor cells are not neurons; no animal or brain-derived seed testing; peptide inhibitors face blood–brain barrier and proteolytic stability hurdles that later reviews emphasize for the peptide-inhibitor class broadly .
    • What would falsify: If VQIINK-targeted caps fail against brain-derived tau seeds, or if brain-seeded amplification shows polymorph-specific inhibition unlike the recombinant tau40 system .

    Confidence: High on structural and in vitro/in-cell claims (directly reported, replicated); low on the tau-strain polymorphism hypothesis, which the authors themselves label speculative.



    Feedback:    

    Updated: November 19, 2026

     BGPT Paper Review



    Study Novelty

    90%

    First atomic-resolution structures of the VQIINK steric zipper via MicroED; first demonstration that VQIINKβ€”not VQIVYKβ€”dominates full-length tau seeding; directly enabled a new inhibitor design strategy.



    Scientific Quality

    80%

    Rigorous crystallography (1.5 Γ…), triplicate assays, blinded analysis, deposited structures. Limitations: heparin-driven aggregation system, HEK293-only cell model, no in vivo validation, and strain hypothesis is speculative.



    Study Generality

    80%

    Steric-zipper inhibitor logic and MicroED application generalize to other amyloid systems; tau-strain polymorphism implications extend beyond Alzheimer's to tauopathies broadly.



    Study Usefulness

    90%

    Provides actionable structural templates (PDB 5V5B/5K7N) and validated inhibitor design logic that directly informs ongoing tau therapeutic efforts.



    Study Reproducibility

    80%

    Deposited PDB coordinates, detailed crystallization/MicroED protocols, commercial peptide sources, and stated replication (triplicate, two independent experiments) support reproduction; no raw data repository beyond PDB.



    Explanatory Depth

    90%

    Explains VQIINK dominance via quantified interface energetics (Sc, Ab), rationalizes Ξ”K280 acceleration structurally, and mechanistically links fuzzy-coat accessibility to seeding sensitivity.


    🎁 Authors: Collect 500 Free Science Tokens (β‰ˆ $50.0 USD)

    Claim My Author Tokens

    Use for 125 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $50.0 USD)

     Top Data Sources ExportMCP



     DataGen



    Generated scientific data; not direct experimental measurements.

     Hypothesis Graveyard



    VQIVYK is the primary target for anti-tau drugs: falsified here by TLKIVW's failure to block tau40 seeding (IC50 poorly defined; combination worse than MINK alone).


    Tau phosphorylation is required for aggregation initiation: contradicted by parallel evidence that tau-tau binding via solid-phase substrates, not phosphorylation, initiates aggregation.

     Science Art


    Paper Review: Structure-based inhibitors of tau aggregation Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT